NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™

Pooled analyses in patients with moderate Alzheimer's show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to mild cognitive function.